​

Funding Round

Post-IPO Equity - Aadi Bioscience

Post-IPO Equity - Aadi Bioscience

Investment Firm

Overview

Aadi Bioscience develops a potentially mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.

Announced Date

Aug 26, 2021

Funding Type

Post Ipo Equity

Highlights

Location

United States, North America

Social

Investor Lead

N/A

Participant Investors

6

Investor Name
Participant InvestorRTW Investments
Participant InvestorBiotechnology Value Fund
Participant InvestorAvoro Capital Advisors
Participant InvestorAcorn Bioventures
Participant InvestorVivo Capital

Round Details and Background

Aadi Bioscience raised $154999876 on 2021-08-26 in Post-IPO Equity

Aadi Bioscience develops a potentially mTOR inhibitor for targeted patient populations in oncology and cardiovascular diseases.

Company Funding History

3

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Aug 26, 2021
Post-IPO Equity - Aadi Bioscience
12-155.0M
Sep 22, 2022
Post-IPO Equity - Aadi Bioscience
5-72.5M
May 08, 2017
Series A - Aadi Bioscience
6-23.0M

Recent Activity

There is no recent news or activity for this profile.